Abstract

BackgroundDespite a demonstrated superiority of interleukin-6 over tumour necrosis factor (TNF) blockade when used as monotherapy, the choice of the first biologic agent (bDMARD) for treating rheumatoid arthritis (RA) in...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call